XTX Topco Ltd Acquires New Stake in AxoGen, Inc. (NASDAQ:AXGN)

XTX Topco Ltd bought a new stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 17,306 shares of the medical equipment provider's stock, valued at approximately $285,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of AXGN. Barclays PLC boosted its holdings in AxoGen by 119.3% in the third quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider's stock valued at $1,010,000 after purchasing an additional 39,182 shares during the period. Geode Capital Management LLC grew its position in shares of AxoGen by 3.2% during the third quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider's stock worth $14,170,000 after buying an additional 31,612 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of AxoGen by 9.8% during the third quarter. Franklin Resources Inc. now owns 76,048 shares of the medical equipment provider's stock worth $1,084,000 after buying an additional 6,767 shares during the period. Principal Financial Group Inc. acquired a new stake in AxoGen in the third quarter valued at approximately $207,000. Finally, JPMorgan Chase & Co. lifted its stake in AxoGen by 2,912.3% in the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider's stock worth $7,697,000 after acquiring an additional 530,775 shares during the last quarter. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at AxoGen

In related news, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total transaction of $264,442.50. Following the completion of the sale, the insider now owns 217,762 shares in the company, valued at $3,810,835. This represents a 6.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy Mcbride Wendell sold 5,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now directly owns 97,899 shares in the company, valued at $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company's stock.

AxoGen Stock Up 5.0 %

NASDAQ:AXGN traded up $0.81 during midday trading on Thursday, hitting $17.08. 188,970 shares of the company were exchanged, compared to its average volume of 428,454. AxoGen, Inc. has a fifty-two week low of $5.55 and a fifty-two week high of $21.00. The company has a market capitalization of $757.44 million, a PE ratio of -53.47 and a beta of 1.00. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The company has a fifty day simple moving average of $17.30 and a 200 day simple moving average of $16.21.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AXGN shares. Canaccord Genuity Group raised their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Cantor Fitzgerald reissued an "overweight" rating and issued a $24.00 target price on shares of AxoGen in a report on Wednesday, March 5th. Finally, Lake Street Capital began coverage on AxoGen in a report on Monday, March 17th. They set a "buy" rating and a $30.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, AxoGen currently has a consensus rating of "Buy" and an average target price of $22.60.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.